Currently, there are 77.09M common shares owned by the public and among those 62.53M shares have been available to trade.
The company’s stock has a 5-day price change of 32.76% and 68.71% over the past three months. REPL shares are trading 25.00% year to date (YTD), with the 12-month market performance up to 2.39% higher. It has a 12-month low price of $6.44 and touched a high of $17.00 over the same period. REPL has an average intraday trading volume of 1.34 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 25.57%, 34.21%, and 12.30% respectively.
Institutional ownership of Replimune Group Inc (NASDAQ: REPL) shares accounts for 93.95% of the company’s 77.09M shares outstanding.
It has a market capitalization of $955.88M and a beta (3y monthly) value of 0.69. The earnings-per-share (ttm) stands at -$3.21. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.79% over the week and 6.04% over the month.
Analysts forecast that Replimune Group Inc (REPL) will achieve an EPS of -0.85 for the current quarter, -0.8 for the next quarter and -2.06 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.92 while analysts give the company a high EPS estimate of -0.92. Comparatively, EPS for the current quarter was -0.78 a year ago. Earnings per share for the fiscal year are expected to increase by 9.79%, and 35.16% over the next financial year. EPS should grow at an annualized rate of 35.14% over the next five years, compared to -14.85% over the past 5-year period.
ROTH MKM coverage for the Replimune Group Inc (REPL) stock in a research note released on August 28, 2024 offered a Buy rating with a price target of $17. Piper Sandler was of a view on April 17, 2023 that the stock is Overweight, while Piper Sandler gave the stock Overweight rating on November 19, 2021, issuing a price target of $52. BTIG Research on their part issued Buy rating on October 15, 2021.
